PEG-IFN-alfa2b/Ribavirin combination therapy for chronic hepatitis C patients with low platelet count: efficacy and safety

PEG-IFN-alfa2b/Ribavirin combination therapy for chronic hepatitis C patients with low platelet count: efficacy and safety - PEG-IFN-alfa2b/Ribavirin combination therapy for CH(C) patients with low platelet count

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002377

Enrollment

100

Registered

2010-04-28

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Peg-IFN-alfa2b/Ribavirin thrapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C Platelet count over 50000/mm3, under 100000/mm3

Exclusion criteria

Exclusion criteria: contraindication of Peg-IFN/Ribavirin thrapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026